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Introduction:
A long-standing clinical challenge in the management of prostate cancer is its heterogeneous response to androgen deprivation therapy (ADT), a standard treatment to disrupt the androgen receptor (AR) signaling pathway, since AR has a profound effect on prostate cancer development through the regulation of not only transcriptional networks but also genomic stability, and the development of gene fusions [1] . While ADT is effective in most patients with prostate cancer, prostate cancers inevitably become resistant to ADT and castration-resistant prostate cancer (CRPC) emerges [2] . Since multiple molecular mechanisms modulating resistance to ADT have been proposed [3] , the recent surge in prostate cancer genomic information may permit molecular classification of prostate cancer [4] . Whole exome sequencing of metastatic castration resistant prostate tumors (mCRPC) from the Michigan cohort [5] and the East Coast Stand Up to Cancer/Prostate Cancer Foundation (SU2C/PCF) study recently revealed that ~10% of tumors harbor promyelocytic leukemia zinc finger (PLZF) genomic alternations [6] . PLZF also known as the zinc finger and BTB-containing protein 16 (ZBTB16) was originally identified as a gene fused to RARα in acute promyelocytic leukemia (APL) patients [7] and was reported as an androgen-responsive tumor suppressor gene [8] . However, the role of PLZF in prostate cancer progression is unclear.
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Accomplishment:
I interrogated the biological consequences of the loss of PLZF expression and performed a bioinformatic analysis of PLZF ChIP seq and PLZF-regulated gene expression profiling to define the PLZF transcriptional program. In addition, I examined the biological function of PLZF in CRPC development in vitro and in vivo Collectively, our data strongly support that PLZF functions as a tumor suppressor in prostate cancer and demonstrate that PLZF inactivation as an important molecular event for CRPC development [9] . What was accomplished under these goals? Task 1. Identify PLZF transcription program mediating castration resistance in prostate cancer cells To interrogate the biological consequences of the loss of PLZF expression, we performed a bioinformatic analysis of PLZF ChIP seq and PLZF-regulated gene expression profiling to define the PLZF transcriptional program ( Figure 1A ). Since AR exerts both growth-promoting and growth-suppressing functions in maintaining the equilibrium between cell differentiation and proliferation, we hypothesized that ADT designed to disrupt AR signaling may stimulate an AR-repressed oncogenic program through PLZF in adaption to ADT, contributing to the castration resistant phenotype [11] . Interestingly, we uncovered that the genes whose expression were up-regulated in PLZF-depleted cells were highly associated with the MAPK pathway, including 5 PLZF direct targets, RRAS, MKNK2, DDIT3, JUND and JUN ( Figure 1B, C, and D) , suggesting that PLZF might be regulating MAPK signaling pathway. Taken together, our data suggest that ADT results in down-regulation of PLZF, which, in turn, activates MAKP activity. These findings are consistent with the findings that MAPK signaling is up-regulated in CRPC patients and murine models [12, 13] . In summary, we propose an intrinsic resistance mechanism through PLZF down regulation or loss, wherein an AR-repressed oncogenic program allows residual prostate tumor cells to adapt to castrate levels of androgens. 
Task 2. Investigate the biological function of PLZF in CRPC development.
We examined the growth of LNCaP cells using 2 additional shRNAs directed at PLZF. These shRNAs also induced androgen-independent growth in LNCaP cells; whereas non-specific silenced (shCtrl) cells did not grow, supporting the findings of the screen [9] . Interestingly, while androgen depletion alone (cultured in CSS) lowers PLZF expression, it is actually the further reduction of PLZF by the shRNAs that promotes growth. As a complementary approach, we also addressed whether PLZF has tumor suppressing effects on cell viability. Importantly, overexpression of PLZF resulted in a profound growth inhibitory effect on PLZF-depleted cells as early as at the first week ( Figure 1C ). It should be noted that the pictures of crystal violet (CV) staining were taken after 3 weeks of CSS incubation which allows shPLZF (#7816)/plx-GFP colonies to accumulate. Taken together, our in vitro experiments functionally show that PLZF is an androgen-responsive gene involved in growth suppression (Figure 2 A-D) . (11) and PLZF as a putative tumor suppressor gene with strongest AR binding merged from two AR cistrome datasets. RT-qPCR and Western blotting were used to measure PLZF mRNA and protein expression of LNCaP cells which were cultured in charcoal-stripped serum (CSS), followed by (B) 10nM of DHT and/or 10µM of bicalutamide (Bic.) treatment. The colonies were stained by crystal violet (CV) and photographed. The efficiency and efficacy of (C) PLZF shRNA knockdown and (D) ectopic re-expression of PLZF was measured by Western blot. Each column was relative to the corresponding the first column and shown as mean ± SD (n ≥ 3), and *p < 0.05.
To block potential AR action, we used enzalutamide to examine the cell growth. Significantly, PLZFdepleted cells initially responded to enzalutamide but rapidly developed resistance, regardless of culturing conditions, indicating that LNCaP cells with PLZF inactivation is growth promoting even in the absence of androgen and further when blocked by enzalutamide as shown below (Figure 3 A-C). To determine the requirement of PLZF loss for androgen-independent growth in vivo, we conducted a mouse xenograft study and showed that tumors with PLZF depletion had a substantial growth advantage as compared to the control (Ctrl) arm in castrated nude mice (Figure 4 A) . To broaden our in vitro and in vivo findings, we investigated PLZF gene expression in different stages of human prostate tumors. The gene expression of PLZF is significantly decreased in mCRPC compared to its expression in primary prostate tumors (Figure 4 B) , indicating that PLZF functions as a tumor suppressor in prostate cancer and its gene expression is decreased in mCRPC. Collectively, our in vitro and in vivo together with human genomic sequencing data strongly support that PLZF functions as a tumor suppressor in prostate cancer and demonstrate that PLZF inactivation as an important molecular event for CRPC development. 
IMPACT:
Promyelocytic Zinc Finger Protein (PLZF) is genetically lost in 5-10% of tumors from metastatic castration resistant prostate cancer (mCRPC) patients who previously were treated with androgen deprivation therapy (ADT) and developed resistance. In addition, PLZF expression can be down-regulated by ADT, since PLZF is a well-known androgen receptor (AR)-stimulated gene. Our data demonstrated that prostate cancer cells in which PLZF loss is mimicked by short hairpin RNA-mediated knockdown exhibited a CRPC and enzalutamide (a second-generation antiandrogen) resistant phenotype in vitro and in vivo. The hope is that this approach to define that patients with PLZF somatic deletions represent a distinct molecular subtype in genetically heterogeneous CRPC, serving as a potential predicative biomarker of drug response to AR-directed therapies, as well as providing a basis for clinical development of personalize therapy. As such, this proposal addresses the Overarching Challenge of "Developing effective treatments and addressing mechanisms of resistance for men with high-risk or metastatic prostate cancer". In so doing, our proposal also addresses the Focus Areas of "Genetics", "Mechanisms of Resistance" and "Therapy".
What was the impact on the development of the principal discipline(s) of the project?
Whole exome sequencing of metastatic castration resistant prostate tumors (mCRPC) from the Michigan cohort and the East Coast Stand Up to Cancer/Prostate Cancer Foundation (SU2C/PCF) study recently revealed that 5~10% of tumors harbor promyelocytic leukemia zinc finger (PLZF) focal homozygous deletions. This cohort of mCRPC patients who were previously were treated with androgen deprivation therapy (ADT) developed castrate resistance. Intriguingly, from a "Genome-Wide RNAi Suppressor Screen", aiming to uncover genes whose silencing were crucial for androgen-independent growth global RNAi screen, we found that PLZF was the only gene that was also induced by androgens, suggesting that PLZF is both androgen-responsive and growth suppressive and may be a part of an AR-repressed oncogenic program essential for developing resistance to ADT.
What was the impact on other disciplines?
"Nothing to Report" What was the impact on technology transfer? "Nothing to Report" What was the impact on society beyond science and technology? "Nothing to Report"
CHANGES/PROBLEMS:
"Nothing to Report"
PRODUCTS:
1. Selected poster "Intensive androgen deprivation therapy compensatorily activates PLZF-repressed oncogenic circuitry that reprograms the residual prostate cancer " for the AACR/PCF Conference: Advances in prostate cancer research (January, 2014, San Diego, CA) 2. AACR-Alfac, Incorporated Scholar-in-Training Award by AACR (January, 2014)
